科研製薬(株)の貸借新規成約高詳細

主市場業種証券コード/EDINET英名称
東証PRM医薬品4521/E00935KAKEN PHARMACEUTICAL CO., LTD.
公表日公表担保新規貸付前週比新規借入(自己)前週比新規借入(転貸)前週比
2019/02/08日証協無担保29,000株+137.7%0株0%0株-100%
2019/02/08日証協有担保32,300株-0.92%46,000株+322.02%30,900株-69.79%
2019/02/01日証協無担保12,200株+1642.86%0株0%2,700株+237.5%
2019/02/01日証協有担保32,600株-50.83%10,900株+141.36%102,300株+197.61%
2019/01/25日証協無担保700株-97.81%0株0%800株-96.9%
2019/01/25日証協有担保66,300株-66.21%4,516株+4416%34,374株+64.44%
2019/01/18日証協無担保32,000株+1291.3%0株-100%25,800株0%
2019/01/18日証協有担保196,200株+109.48%100株-98.98%20,904株-69.2%
2019/01/11日証協無担保2,300株-90.65%2,800株0%0株-100%
2019/01/11日証協有担保93,661株+159.85%9,800株+3916.39%67,868株+261%
2019/01/04日証協有担保36,044株-63.5%244株-97.44%18,800株-78.96%
2018/12/28日証協無担保24,600株+9999.99%0株0%2,500株-13.79%
2018/12/28日証協有担保98,744株+49.98%9,544株-38.71%89,365株+196.33%
2018/12/21日証協無担保200株-97.92%0株0%2,900株-87.92%
2018/12/21日証協有担保65,836株-48.46%15,573株+28.36%30,157株-62.86%
2018/12/14日証協無担保9,600株0%0株0%24,002株+445.5%
2018/12/14日証協有担保127,730株-16.52%12,132株+428.4%81,200株+114.25%
2018/12/07日証協無担保0株-100%0株0%4,400株+100%
2018/12/07日証協有担保153,003株-42.46%2,296株-96.98%37,900株-52.01%
2018/11/30日証協無担保18,200株+52.94%0株0%2,200株+1000%
2018/11/30日証協有担保265,888株+580.18%76,102株+9999.99%78,980株+103.56%
2018/11/22日証協無担保11,900株-6.3%0株0%200株-98.08%
2018/11/22日証協有担保39,091株-50.21%300株+3.09%38,800株+14.93%
2018/11/16日証協無担保12,700株+1487.5%0株0%10,400株0%
2018/11/16日証協有担保78,514株-33.84%291株-97.14%33,760株-55.31%
2018/11/09日証協無担保800株+60%0株0%0株-100%
2018/11/09日証協有担保118,668株+25.72%10,191株+2506.39%75,550株+183.81%
2018/11/02日証協無担保500株+66.67%0株0%100株0%
2018/11/02日証協有担保94,392株-43.68%391株-27.73%26,620株+38.13%
2018/10/26日証協無担保300株-94.44%0株-100%100株-87.5%
2018/10/26日証協有担保167,603株+48.01%541株-48.03%19,272株-70.4%
2018/10/19日証協無担保5,400株+260%400株+33.33%800株+166.67%
2018/10/19日証協有担保113,241株+49.99%1,041株-55.53%65,118株+80.05%
2018/10/12日証協無担保1,500株-98.88%300株0%300株-90.67%
2018/10/12日証協有担保75,497株-65.99%2,341株-19.28%36,166株-58.76%
2018/10/05日証協無担保133,600株+1022.69%0株0%3,216株-21.56%
2018/10/05日証協有担保221,982株+489.73%2,900株-92.75%87,700株+712.04%

※株式分割は考慮していませんのでご注意ください。

Page Top